These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 22388169)

  • 1. The declining use of reboxetine in years 2000 to 2006: a pharmacoepidemiological comparative study.
    Parabiaghi A; Franchi C; Tettamanti M; Barbato A; D'Avanzo B; Fortino I; Bortolotti A; Merlino L; Nobili A
    J Clin Psychopharmacol; 2012 Apr; 32(2):303-5. PubMed ID: 22388169
    [No Abstract]   [Full Text] [Related]  

  • 2. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
    Andreoli V; Caillard V; Deo RS; Rybakowski JK; Versiani M
    J Clin Psychopharmacol; 2002 Aug; 22(4):393-9. PubMed ID: 12172339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial.
    Taner E; Demir EY; Cosar B
    Adv Ther; 2006; 23(6):974-87. PubMed ID: 17276965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis.
    Sun Y; Liang Y; Jiao Y; Lin J; Qu H; Xu J; Zhao C
    BMJ Open; 2017 Aug; 7(8):e016499. PubMed ID: 28775189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials.
    Eyding D; Lelgemann M; Grouven U; Härter M; Kromp M; Kaiser T; Kerekes MF; Gerken M; Wieseler B
    BMJ; 2010 Oct; 341():c4737. PubMed ID: 20940209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deciding which selective serotonin reuptake inhibitor to prescribe.
    Cleare AJ
    BMJ; 1995 Dec; 311(7020):1641. PubMed ID: 8555826
    [No Abstract]   [Full Text] [Related]  

  • 7. [Unfortunate title?].
    Waern M; Agren H; Hägglöf B; Lundin B
    Lakartidningen; 2004 Jun; 101(26-27):2292. PubMed ID: 15281636
    [No Abstract]   [Full Text] [Related]  

  • 8. Do noradrenaline and serotonin differentially affect social motivation and behaviour?
    Dubini A; Bosc M; Polin V
    Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S49-55; discussion S71-3. PubMed ID: 9169310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
    Fava M; McGrath PJ; Sheu WP;
    J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of reboxetine in depressive patients treated in routine clinical practice.
    Messer T; Schmauss M; Lambert-Baumann J
    CNS Drugs; 2005; 19(1):43-54. PubMed ID: 15651904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neonatal complications after intrauterine exposure to SSRI antidepressants.
    Prescrire Int; 2004 Jun; 13(71):103-4. PubMed ID: 15233148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Depressed, lacking motivation, unconcentrated. Signs of central deficiency of noradrenaline].
    MMW Fortschr Med; 2004 Jul; 146(27-28):56. PubMed ID: 15526675
    [No Abstract]   [Full Text] [Related]  

  • 13. [SSRI resistant depression. Supplementation with noradrenergic pharmaceuticals can be a good alternative].
    Bodlund O; Häggström L
    Lakartidningen; 2004 Sep; 101(36):2712-4. PubMed ID: 15455633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful management of depression with reboxetine in a patient who developed Parkinsonism related to paroxetine use.
    Kuloglu M; Caykoylu A; Ekinci O; Bayindirli D; Vural G; Deniz O
    J Psychopharmacol; 2010 Apr; 24(4):623-4. PubMed ID: 19074535
    [No Abstract]   [Full Text] [Related]  

  • 15. Antidepressant Prescriptions, Including Tricyclics, Continue to Increase in Canadian Children.
    Lukmanji A; Pringsheim T; Bulloch AG; Stewart DG; Chan P; Tehrani A; Patten SB
    J Child Adolesc Psychopharmacol; 2020 Jul; 30(6):381-388. PubMed ID: 31895595
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of serotonin and noradrenaline in social dysfunction: a review of data on reboxetine and the Social Adaptation Self-evaluation Scale (SASS).
    Keller M
    Gen Hosp Psychiatry; 2001; 23(1):15-9. PubMed ID: 11226552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A question of balance.
    Ramchandani P
    Nature; 2004 Jul; 430(6998):401-2. PubMed ID: 15269742
    [No Abstract]   [Full Text] [Related]  

  • 18. Antidepressant effectiveness in severe depression and melancholia.
    Schatzberg AF
    J Clin Psychiatry; 1999; 60 Suppl 4():14-21; discussion 22. PubMed ID: 10086479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective serotonin reuptake inhibitors in children and adolescents with major depression.
    Scahill L
    Braz J Psychiatry; 2005 Jun; 27(2):91-2. PubMed ID: 15962129
    [No Abstract]   [Full Text] [Related]  

  • 20. The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step.
    Brent DA
    Depress Anxiety; 2009; 26(10):871-4. PubMed ID: 19798756
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.